Did you know that 10-20% of lung cancer patients have never smoked? Is it worth it to quit smoking after a lung cancer diagnosis? Some of these myths may surprise you.
The annual congress of American Society of Clinical Oncology is the most important meeting of oncologists worldwide, with about 35,000 delegates. This year, in lung cancer and mesothelioma, several developments were announced with interest to patients.
Professor Håkan Mellstedt is a medical oncologist at the Cancer Center Karolinska in Sweden, with extensive clinical and academic experience. In this article, Prof. Mellstedt, also a member of our Scientific Committee, explains the basics of immunotherapy and key research being conducted across cancer types.
“A bad attitude is like a flat tire. If you don’t change it you’ll never go anywhere.” Some patients have gotten this 100% right, and they apply this principle both during and after their treatments. And if you like quotes, here’s one to write down: “Fear isn’t real, it’s all in your head”.
Federico Cappuzzo is an expert in personalized treatment for lung cancer. We recently asked him to address important issues for patients’ lung cancer screening and treatment.
Targeted therapy is a new development in oncology, which attacks cancer cells but does less damage to normal cells. Professor Tony Mok, a member of the CareAcross Scientific Committee, is an expert in targeted treatments for lung cancer. In this article, he answers 4 important questions relevant to anyone affected by lung cancer.
Dr. Enriqueta Felip, member of the CareAcross Scientific Committee, is a renowned expert in lung cancer. She holds a PhD in Medical Oncology, and has broad experience in cancer research as well as clinical practice. We recently asked her a few questions on lung cancer, and here are her responses.